Carrie Mosher Email & Phone Number

Leominster, Massachusetts, United States

One of the top three salespeople for 5 years in a rowCertified in Specialized BG Fit level 1 and level 2 as well as VelogicFit softwareOperations leader, developing SOP for the company and performing daily operational tasks (receiving, inventory, transfers)Web sales member, managing backorders and ensuring customer satisfactionOperator on website chat help, sales for all seven locations as well as customer service

Cambridge, Ma

• Part of team to develop Prometheus, internal compound and analytical ordering software• Liaison between Analytical Chemistry and Medicinal Chemistry• Instituted and streamlined the analytical compound management procedure within analytical chemistry and prioritized incoming requests for analysis• Responsible for developing assays on and operation of newly installed Agilent UHPLC/TOF and AbSciex triple quad instruments as well as optimization of established methods on Waters Acquity UPLC instruments• Conducted pre-clinical physicochemical characterization: solubility, PBS and glutathione stability, plasma protein binding and plasma stability, microsomal stability, CYP reaction phenotyping, CYP inhibition

• Incubated hydroxywarfarin in human liver microsomes, quantitated the glucuronide metabolites via LC-MS/MS (AbSciex ion trap), and performed statistical analysis to determine the contribution of various genetic factors to the UGT metabolic variation• Quantitated the plasma levels of aspirin and salicylic acid from dogs as well as citalopram from human patients• Analyzed the stability and cellular localization of UGT genetic variants using mammalian cell transfection, Western blotting and confocal microscopic techniques• Examined the epigenetic contribution to expression variation of CYP3A4 in liver samples utilizing PCR, RT-PCR, and bisulfite-modification of DNA

Seattle, Wa

• Developed assays for metabolite quantitation that included HPLC (reverse-phase, size exclusion, and chiral) and LC-MS/MS (Agilent MSD, Micromass Quattro triple quad)• Engineered site-directed mutants of CYP2C9, 2B6, 2J2, and 26A1, expressed using the Escherichia coli system, and purified using nickel affinity chromatography• Analyzed CYP2C9 enzyme kinetics of warfarin, flurbiprofen and phenytoin, including the cooperative kinetics of lansoprazole with phenytoin• Measured ligand T1 relaxation rates with CYP2C9’s binding site via protein NMR• Modeled the binding of CYP2C9 ligands (including cooperative ligands) using Autodock

Developed HPLC and GC methods for contracted quality assurance cosmetic samplesExtracted active ingredients from cosmetic samples and herbal supplements using liquid-liquid or solid-phase extractionAssisted in neuropharmacology laboratory with focus on alcoholismCollaborated with Idaho National Engineering and Environmental Laboratory

Doctor Of Philosophy, Medicinal Chemistry (Drug Metabolism Biochemistry)

Thesis: CYP2C9 Binding Determinants and Activation Mechanisms for Phenytoin and (S)-Warfarin Metabolism Advisor: Allan Rettie

Master Of Science, Pharmacy (Pharmaceutical Chemistry)

Thesis: Analytical high-performance liquid chromatography studies on valerenic acids and valerian based preparations Advisor: Eric J. Jarvi

Bs, Biology/Environmental Science